Tempus AI has acquired the pharmacogenetics assets of OneOme, a once-promising precision medicine startup that abruptly shut down earlier this year amid financial troubles. The deal marks the latest in a flurry of acquisitions by Tempus as it races to build one of the most comprehensive data and AI platforms in healthcare.
OneOme, launched by the Mayo Clinic and the University of Minnesota, was known for its clinically validated PGx testing, which helps physicians understand how genetic variation influences a patient’s response to medications. But despite strong scientific underpinnings and early market traction, the company was unable to sustain operations and folded before ultimately selling off its assets.
For Tempus, the addition of OneOme’s PGx capabilities fills a strategic gap. Pharmacogenetics has become an increasingly valuable layer in clinical decision-making, particularly as health systems and payers push for more personalized, evidence-based prescribing. By pulling OneOme’s assets into its ecosystem, Tempus can strengthen its position in AI-enabled precision medicine by expanding its datasets and testing capabilities across various disease categories.
A Year of Aggressive Expansion
The OneOme pickup is part of a broader acquisition spree that has defined Tempus’ strategy throughout 2025. The company has spent the year consolidating data-rich assets across pathology, genomics, and clinical trial matching, each one feeding into its push to build large-scale, multimodal AI models.
Earlier this year, Tempus acquired Paige, the digital pathology pioneer, for $81.25 million. That move brought nearly seven million digitized pathology slides into Tempus’ growing data lake and bolstered its efforts to develop foundation models capable of analyzing cancer tissue at scale.
Tempus also bought Deep 6 AI, expanding its footprint in clinical trial recruitment. Deep 6’s technology, already connected to more than 750 provider locations, is expected to help Tempus streamline trial matching by tapping into millions of patient records.
Perhaps the strongest signal of Tempus’ ambitions came with its $600 million acquisition of Ambry Genetics. The deal dramatically expanded Tempus’ testing portfolio in hereditary cancer, rare disease, and women’s health—and added a major volume of genomic data to fuel AI development.
Positioning for the Next Phase of AI in Healthcare
With the addition of OneOme’s pharmacogenetics tools, Tempus is stitching together one of the most vertically integrated data platforms in precision medicine. The company now controls large-scale assets spanning tissue imaging, genomic sequencing, PGx, and real-world clinical records, exactly the multimodal inputs required to train powerful clinical AI systems.
As competition intensifies across the AI-in-healthcare landscape, Tempus’ acquisition strategy signals a clear trajectory: build the deepest, broadest dataset possible, and use it to power the next generation of clinical decision-support tools. In an industry where data is currency, Tempus is positioning itself as one of the few players capable of defining what AI-enabled medicine looks like in the years ahead.
